

Munich Cancer Registry



- ▶ Incidence and Mortality
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

Mammarian Paget disease

Survival

Year of diagnosis	1998-2019
Patients	296
Diseases	296
Cases evaluated	247
Creation date	01/28/2021
Database export	01/07/2021
Population (females)	2.48 m



Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninstr. 15
Munich, 81377
Germany

<https://www.tumorregister-muenchen.de/en>

https://www.tumorregister-muenchen.de/en/facts/surv/sMPDf_E-Mammarian-Paget-disease-survival.pdf

Index of figures and tables

Fig./Tbl.		Page
1a	Relative survival by period of diagnosis (chart)	3
1b	Survival by period of diagnosis (table)	3
2a	Survival of total cohort (chart)	4
2b	Survival of total cohort (table)	4
3a	Observed survival by age category (chart)	5
3b	Relative survival by age category (chart)	5
3c	Survival by age category (table)	6
4a	Observed survival by histology (chart)	7
4b	Relative survival by histology (chart)	7
4c	Survival by histology (table)	8
5a	Time to first progression (chart)	9
5b	Time to first progression (table)	9




Figure 1a. Relative survival of patients with mammary Paget disease by period of diagnosis. Included in the evaluation are 236 cases diagnosed between 1998 and 2019.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Period of diagnosis			
	1998-2006 n=86		2007+ n=150	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	97.7	99.9	93.6	96.6
2	90.6	94.4	90.4	95.8
3	83.5	87.9	89.5	96.8
4	74.1	80.0	85.5	95.4
5	71.7	79.3	83.2	95.7
6	70.5	79.4	81.5	97.6
7	68.1	78.7	77.7	95.0
8	65.7	77.2	75.4	94.4
9	63.2	76.6	73.0	93.9
10	60.5	75.3	73.0	94.2
11	59.2	74.9		
12	55.1	72.7		
13	52.2	70.3		
14	50.6	69.8		
15	48.6	68.8		
Median	14.6			

Table 1b. Observed (obs.) and relative (rel.) survival of patients with mammary Paget disease by period of diagnosis for period 1998-2019 (N=236).




Figure 2a. Observed, expected and relative survival of the total cohort with mammalian Paget disease. Included in the evaluation are 236 cases diagnosed between 1998 and 2019.

Years	Group	
	obs. %	rel. %
0	100.0	100.0
1	95.1	97.9
2	90.3	95.2
3	86.8	93.4
4	80.3	88.8
5	77.9	88.6
6	76.5	89.7
7	73.6	88.2
8	71.1	87.0
9	68.6	86.5
10	66.7	85.9
11	62.6	83.2
12	57.5	78.7
13	54.6	76.2
14	52.9	75.7
15	50.8	74.5
Median	16.5	

Table 2b. Observed (obs.) and relative (rel.) survival of the total cohort with mammalian Paget disease for period 1998-2019 (N=236).




Figure 3a. Observed survival of patients with mammarian Paget disease by age category. Included in the evaluation are 236 cases diagnosed between 1998 and 2019.




Figure 3b. Relative survival of patients with mammarian Paget disease by age category. Included in the evaluation are 236 cases diagnosed between 1998 and 2019.

Years	Age category			
	0-59 yrs n=83		60+ yrs n=153	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	98.7	98.7	93.2	97.3
2	97.3	97.8	86.6	93.8
3	95.9	95.7	81.9	91.6
4	92.8	93.0	73.5	85.9
5	91.2	91.8	70.7	86.8
6	91.2	91.2	68.5	88.7
7	89.2	90.9	65.0	87.6
8	89.2	90.8	61.1	85.6
9	89.2	90.6	57.2	84.7
10	89.2	90.4	54.2	83.6
Median			11.0	

Table 3c. Observed (obs.) and relative (rel.) survival of patients with mammalian Paget disease by age category for period 1998-2019 (N=236).




Figure 4a. Observed survival of patients with mammarian Paget disease by histology. For 236 of 236 cases diagnosed between 1998 and 2019 valid data could be obtained for this item.




Figure 4b. Relative survival of patients with mammarian Paget disease by histology. For 236 of 236 cases diagnosed between 1998 and 2019 valid data could be obtained for this item.

Years	Histology					
	Paget disease n=34		Paget disease + DCIS n=135		Paget disease + IDC n=67	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	100.0	100.0	96.9	99.7	89.2	92.0
2	96.2	99.1	93.7	98.8	80.5	84.9
3	92.1	94.2	91.2	98.1	75.0	79.5
4			85.8	95.0	64.9	70.9
5			84.9	96.5	57.7	65.5
6			83.8	98.3		
7			81.5	97.7		
8			77.7	95.5		
9			75.2	94.8		
10			72.4	93.3		
11			68.1	91.3		
12			64.5	87.9		
13			62.5	86.9		
14			62.5	87.1		
15			59.5	86.5		
Median						

Table 4c. Observed (obs.) and relative (rel.) survival of patients with mammalian Paget disease by histology for period 1998-2019 (N=236).




Figure 5a. Time to first progression of 235 patients with mammarian Paget disease diagnosed between 1998 and 2019 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

	Type of progression							Distant metastasis (CI)
	Any type (CI)	Any type (1-KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)		
N	224	224	235	235	235	235	225	
Events	27	27	11	11	2	2	13	
compet.	43		64		69		50	
Years	%	%	%	%	%	%	%	
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
1	2.8	2.9	0.5	0.5	0.4	0.5	1.4	
2	5.3	5.5	2.3	2.5	0.4	0.5	2.4	
3	9.7	10.1	4.9	5.4	1.0	1.1	4.5	
4	11.4	12.0	4.9	5.4	1.0	1.1	5.1	
5	12.1	12.8	5.6	6.2	1.0	1.1	5.1	
6	12.8	13.6	5.6	6.2	1.0	1.1	5.8	
7	13.6	14.6	5.6	6.2	1.0	1.1	6.6	
8	13.6	14.6	5.6	6.2	1.0	1.1	6.6	
9	14.5	15.8	5.6	6.2	1.0	1.1	7.5	
10	15.6	17.1	5.6	6.2	1.0	1.1	7.5	
11	15.6	17.1	5.6	6.2	1.0	1.1	7.5	
12	15.6	17.1	5.6	6.2	1.0	1.1	7.5	
13	15.6	17.1	5.6	6.2	1.0	1.1	7.5	
14	15.6	17.1	5.6	6.2	1.0	1.1	7.5	
15	15.6	17.1	5.6	6.2	1.0	1.1	7.5	

<i>cont'd</i>	Type of progression		
	Distant metast. (1-KM)	NOS (CI)	NOS (1-KM)
N	225	234	234
Events	13	7	7
compet.		64	
Years	%	%	%
0	0.0	0.0	0.0
1	1.5	0.4	0.4
2	2.5	0.9	1.0
3	4.8	1.9	2.1
4	5.4	3.0	3.4
5	5.4	3.0	3.4
6	6.3	3.0	3.4
7	7.2	3.0	3.4
8	7.2	3.0	3.4
9	8.4	3.0	3.4
10	8.4	4.0	4.8
11	8.4	4.0	4.8
12	8.4	4.0	4.8
13	8.4	4.0	4.8
14	8.4	4.0	4.8
15	8.4	4.0	4.8

Table 5b. Time to first progression of patients with mammarian Paget disease for period 1998-2019 (N=235), also showing the total of progression events (Events) and of deaths as competing risk (compet.).

Shortcuts

MCR Munich Cancer Registry, Germany

NCI National Cancer Institute, USA

SEER Surveillance, Epidemiology, and End Results, USA

UICC Union for International Cancer Control, Geneva

DCO Death certificate only Death certificate provides the only notification to the registry.

NA Not available

NOS Not otherwise specified

OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate)
Date of entry: diagnosis
Event: death from any cause

RS Relative survival Survival compared to “general population”,
ratio of observed to expected survival (Ederer II method),
reflecting cancer specific survival

AS Assembled survival Assembled chart of
observed, expected, relative survival

CS Conditional survival Survival probability under the condition of surviving
a given period of time

TTP Time to progression Time to first progression / relapse
Date of entry: diagnosis
Event: (progression / relapse): first local-, lymph node recurrence,
distant metastasis or unspecified progression

1-KM 1 minus Kaplan-Meier estimator
 (“inverse” Kaplan-Meier estimator)

CI Cumulative incidence
Death as competing risk (according to Kalbfleisch und Prentice)

PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate)
Date of entry (progression / relapse): first local-, lymph node
recurrence, distant metastasis or unspecified progression
Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival Mammarian Paget disease [Internet]. 2021 [updated 2021 Jan 28; cited 2021 Mar 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sMPDf_E-Mammarian-Paget-disease-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.